VOR Stock Analysis: Vor Biopharma | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.116m USD | 12M Return: -62.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 19.8M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Vor Biopharma Inc. is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases. Its lead candidate, telitacicept, is a fusion protein being evaluated for generalized myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, Sjögrens disease, and IgA nephropathy. The company does not own the original discovery of telitacicept; instead, it holds a license agreement with RemeGen Co., Ltd. for the development and commercialization of the drug and related products in its territories. As a clinical-stage company, Vor Biopharma has no products approved for commercial sale and generates revenue (if any) primarily through collaboration or licensing arrangements rather than product sales.
The company was incorporated in 2015 and is headquartered in Boston, Massachusetts, a major U.S. hub for biotechnology firms. It trades on the NASDAQ under the ticker VOR and is classified within the Biotechnology sub-industry of the Health Care sector. Like many small-cap clinical-stage biotechs, its valuation reflects investor expectations tied to pipeline progress and clinical trial outcomes rather than current revenue or earnings.
- Telitacicept Phase 3 autoimmune trial readouts near
- FDA review of RemeGen China-sourced clinical data critical
- Cash burn accelerates ahead of pivotal trial milestones
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -1.69 > 0.02 and ΔFCF/TA -70.79 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.30 > 3% & CFO -149.9m > Net Income -883.1m |
| Net Debt (-488.6m) to EBITDA (449.1m): -1.09 < 3 |
| Current Ratio: 31.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (430k) vs 12m ago -93.11% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 3.37%; Δ -3.37% > 0%) |
| Interest Coverage Ratio: 0.34 > 6 (EBIT TTM 447.0m / Interest Expense TTM 1.33b) |
| A: 0.96 (Total Current Assets 500.8m - Total Current Liabilities 16.1m) / Total Assets 506.7m |
| B: -2.71 (Retained Earnings -1.37b / Total Assets 506.7m) |
| C: 1.45 (EBIT TTM 447.0m / Avg Total Assets 308.0m) |
| D: -0.23 (Book Value of Equity -150.4m / Total Liabilities 657.2m) |
| Altman-Z'' = 6.96 = AAA |
As of July 08, 2026, the stock is trading at USD 20.10 with a total of 1,369,023 shares traded. Over the past week, the price has changed by +8.06%, over one month by +51.24%, over three months by +19.29% and over the past year by -62.36%.
Current recommended Stop Loss: 18.50 (which is 8% or 1.2 ATR below the current price).
Vor Biopharma has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold VOR.
- StrongBuy: 0
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 37.9 | 88.5% |
P/B = 0.6555
Revenue TTM = 0.0 USD
EBIT TTM = 447.0m USD
EBITDA TTM = 449.1m USD
Long Term Debt = 2.63m USD (estimated: total debt 2.94m - short term 307k)
Short Term Debt = 307k USD (from shortTermDebt, last quarter)
Debt = 2.94m USD (from shortLongTermDebtTotal, last quarter) (leases 2.94m already included)
Net Debt = -488.6m USD (calculated: Debt 2.94m - CCE 491.5m)
Enterprise Value = 627.1m USD (1.12b + Debt 2.94m - CCE 491.5m)
Interest Coverage Ratio = 0.34 (Ebit TTM 447.0m / Interest Expense TTM 1.33b)
EV/FCF = -0.73x (Enterprise Value 627.1m / FCF TTM -854.1m)
FCF Yield = -136.2% (FCF TTM -854.1m / Enterprise Value 627.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 1.24 (Enterprise Value 627.1m / Total Assets 506.7m)
Interest Expense / Debt = 45.3k% (Interest Expense 1.33b / Debt 2.94m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 353.2m (EBIT 447.0m * (1 - 21.00%))
Current Ratio = 29.25 (Total Current Assets 500.8m / Total Current Liabilities 17.1m)
Debt / Equity = -0.02 (negative equity) (Debt 2.94m / totalStockholderEquity, last quarter -150.4m)
Debt / EBITDA = -1.09 (Net Debt -488.6m / EBITDA 449.1m)
Debt / FCF = 0.57 (negative FCF - burning cash) (Net Debt -488.6m / FCF TTM -854.1m)
Total Stockholder Equity = -1.01b (last 4 quarters mean from totalStockholderEquity)
RoA = -286.7% (out of range, set to none)
RoE = 87.31% (negative equity) (Net Income TTM -883.1m / Total Stockholder Equity -1.01b)
RoCE = -44.31% (negative capital employed) (EBIT 447.0m / Capital Employed (Equity -1.01b + L.T.Debt 2.63m))
RoIC = 71.93% (NOPAT 353.2m / Invested Capital 491.0m)
WACC = 11.52% (E(1.12b)/V(1.12b) * Re(11.55%) + (debt cost/tax rate unavailable))
Discount Rate = 11.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 60.0 | Cagr: -60.08%
[DCF] Fair Price = unknown (Cash Flow -854.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.00 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.70 | Chg30d=+0.00% | Revisions=-17% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.77 | Chg30d=+0.00% | Revisions=-17% | Analysts=2
EPS current Year (2026-12-31): EPS=-6.90 | Chg30d=+0.00% | Revisions=-50% | GrowthEPS=+90.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.74 | Chg30d=-1.02% | Revisions=+17% | GrowthEPS=+45.8% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -27% (up=4, down=8)